D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
CytoSorbents Analyst Ratings
Balanced Hold Rating Amid Revenue Miss and Strategic Initiatives at CytoSorbents
H.C. Wainwright Maintains Cytosorbents(CTSO.US) With Hold Rating, Maintains Target Price $1
Cytosorbents Price Target Maintained With a $10.00/Share by EF Hutton
Cytosorbents Is Maintained at Buy by EF Hutton
CytoSorbents Analyst Ratings
B.Riley Financial Maintains Cytosorbents(CTSO.US) With Buy Rating, Cuts Target Price to $3
CytoSorbents Analyst Ratings
Cytosorbents Price Target Maintained With a $10.00/Share by EF Hutton
CytoSorbents Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target
CytoSorbents Stability and Growth Prospects Maintain 'Hold' Rating Amid FDA Submission Uncertainty
H.C. Wainwright Maintains Cytosorbents(CTSO.US) With Hold Rating, Maintains Target Price $1
EF Hutton Maintains Cytosorbents(CTSO.US) With Buy Rating, Raises Target Price to $10
CytoSorbents Analyst Ratings
EF Hutton Initiates Coverage On CytoSorbents With Buy Rating, Announces Price Target of $10
B. Riley Securities: Reiterated CytoSorbents (CTSO.US) rating and adjusted from buy to buy rating, target price of $3.00.
CytoSorbents Analyst Ratings
Hold Rating on Cytosorbents Amid Regulatory Uncertainties and Mixed Clinical Results